The Institute for Safe Medication Practices, a nonprofit organization that reports on medication safety is today releasing a new report that will include hepatitis C medications; Sovaldi and Harvoni. Yesterday, an article published in The New York Times referenced the report, read the article, here.
QuarterWatch published the report today.
PERSPECTIVES FROM NEW ADVERSE EVENT REPORTS
Antidepressants, allergy drugs among 87 products with signals for insomnia
Liver failure and antiviral failure with hepatitis C direct-acting drugs
Harms of antipsychotic drugs reappraised
Liver failure and antiviral failure with hepatitis C direct-acting drugs
Harms of antipsychotic drugs reappraised
Download PDF here...
Perspective
Report raises questions about long-term effects of DAAs for HCV
January 25, 2017
Researchers raised questions about the long-term safety of direct-acting antivirals for hepatitis C virus infection after an analysis of FDA data uncovered more than 500 reports of liver failure and more than 1,000 reports of severe liver injury related to the drugs over one recent 12-month period.
Report raises questions about long-term effects of DAAs for HCV
January 25, 2017
Researchers raised questions about the long-term safety of direct-acting antivirals for hepatitis C virus infection after an analysis of FDA data uncovered more than 500 reports of liver failure and more than 1,000 reports of severe liver injury related to the drugs over one recent 12-month period.
Continue reading @ Healio
No comments:
Post a Comment